LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
"Multiple myeloma dynamics require changes to reimb strategy
by
Whang, byung-woo
Oct 22, 2024 05:51am
"Multiple myeloma is a cancer type that has a great ripple effect depending on new drugs provided in a certain environment. Reimbursement of multiple myeloma treatment requires discussion following a thorough evaluation of the impact of the treatment depending on the treatment environment." Multiple myeloma is one of the cancer types wit
Company
Will combination therapies for cancer be reimbursed in KOR?
by
Whang, byung-woo
Oct 21, 2024 05:49am
As the government has begun to prepare the principles for the reimbursement review of combination therapies that use new anticancer drugs, attention is being paid to whether the discussion will progress further. According to industry sources, the Health Insurance Review and Assessment Service recently held a Cancer Disease Deliberation C
Company
Therapeutic device 'improves OS for lung cancer patients'
by
Son, Hyung Min
Oct 21, 2024 05:48am
The first therapeutic device has been approved for use in non-small cell lung cancer (NSCLC). Novocure's therapeutic device, in combination with an NSCLC medication, demonstrated to improve patients' overall survival and won the approval of the U.S. regulatory authority. In South Korea, Nu Eyne is researching the potential of oncology therapeuti
Company
Oxlumo receives orphan drug designation in Korea
by
Eo, Yun-Ho
Oct 21, 2024 05:48am
The primary hyperoxaluria treatment Oxlumo received orphan drug designation in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced the designation through an orphan drug designation notice. Oxlumo (lumasiran) was also recently designated a Global Innovative products on Fast Track (GIFT) by the MFDS. The drug is an
Company
RNAi therapeutic 'Givlaari' receives the ODD in KOR
by
Eo, Yun-Ho
Oct 21, 2024 05:48am
RNAi therapeutic 'Givlaari' has been designated as an orphan drug following its designation as the GIFT. The Ministry of Food and Drug Safety (MFDS) recently announced this through the posting of the Orphan Drug Designation (ODD). Givlaari (givosiran) had previously been designated as the 'Global Innovative products on Fast Track (GIF
Company
Bladder cancer drug Balversa offers new treatment option
by
Whang, byung-woo
Oct 18, 2024 05:49am
The introduction of the targeted therapy Balversa (erdafitinib) in urothelial carcinoma has attracted attention for its potential to address unmet needs. In particular, the emergence of FGFR inhibitors has highlighted the importance of genetic mutation diagnostics to quickly detect the presence of such mutations. Inho Kim, professor o
Company
'Vorasidenib' receives Orphan Drug Designation in KOR
by
Eo, Yun-Ho
Oct 18, 2024 05:49am
'Vorasidenib,' an anticancer drug targeting brain cancer, has been designated an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) announced this on October 8th through the Orphan Drug Designation (ODD) notice. Vorasidenib is an orally administered dual inhibitor of isocitrate dehydrogenase (IDH) 1/2 that selectiv
Company
Will blockbuster contraception Mercilon find a new provider?
by
Nho, Byung Chul
Oct 18, 2024 05:49am
As Alvogen Korea and Chong Kun Dang's co-promotion contracts for oral birth control pills are set to expire, many pharmaceutical¡¤distributors are sending love calls. Sources said that distributors, including pharmaceutical companies with strength in over-the-counter drug sales, have visited Alvogen Korea and Chong Kun Dang to weigh co
Company
oHCM drug Camzyos's last hurdle to reimb remains high
by
Eo, Yun-Ho
Oct 15, 2024 05:50am
The reimbursement journey for ¡®Camzyos¡¯, which is seeking insurance reimbursement in Korea, is going to be a rocky road until the end. According to industry sources, the drug pricing negotiations between BMS Pharmaceuticals Korea and the National Health Insurance Service (NHIS) for the obstructive hypertrophic cardiomyopathy (oHCM) drug
Company
¡°Market for veterinary drugs expected to grow rapidly¡±
by
Son, Hyung Min
Oct 15, 2024 05:50am
¡°MSD Animal Health Korea¡¯s clients are animals. We believe that the drug distribution channels for animals should be carefully designed to contribute to the health of animals in Korea. Supplying our products to animals that need them quickly, sufficiently, and safely is the biggest principle in designing our domestic distribution network.
1
2
3
4
5
6
7
8
9
10
>